Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.79% | -1.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.87% | 14.85% | |||
| Operating Income | -42.87% | -14.85% | |||
| Income Before Tax | -169.22% | 15.61% | |||
| Income Tax Expenses | 6,939.13% | -168.66% | |||
| Earnings from Continuing Operations | -193.54% | 16.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -193.54% | 16.24% | |||
| EBIT | -42.87% | -14.85% | |||
| EBITDA | -42.98% | -14.89% | |||
| EPS Basic | -184.41% | 27.52% | |||
| Normalized Basic EPS | -190.90% | 37.06% | |||
| EPS Diluted | -184.41% | 27.52% | |||
| Normalized Diluted EPS | -190.90% | 37.06% | |||
| Average Basic Shares Outstanding | 3.21% | 15.56% | |||
| Average Diluted Shares Outstanding | 3.21% | 15.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||